Oramed Pharmaceuticals (ORMP) Downgraded to “Sell” at ValuEngine
ValuEngine downgraded shares of Oramed Pharmaceuticals (NASDAQ:ORMP) from a hold rating to a sell rating in a research report sent to investors on Tuesday.
Several other research firms also recently commented on ORMP. HC Wainwright reiterated a buy rating and set a $25.00 price objective on shares of Oramed Pharmaceuticals in a research note on Wednesday, November 22nd. B. Riley reiterated a buy rating and set a $20.00 price objective on shares of Oramed Pharmaceuticals in a research note on Tuesday, January 16th.
Shares of Oramed Pharmaceuticals (NASDAQ:ORMP) opened at $7.40 on Tuesday. The firm has a market cap of $106.34, a P/E ratio of -9.61 and a beta of 0.22. Oramed Pharmaceuticals has a one year low of $5.85 and a one year high of $11.34.
Large investors have recently bought and sold shares of the company. Wells Fargo & Company MN lifted its stake in shares of Oramed Pharmaceuticals by 4.4% during the second quarter. Wells Fargo & Company MN now owns 14,725 shares of the biotechnology company’s stock worth $114,000 after buying an additional 625 shares during the period. Millennium Management LLC acquired a new stake in shares of Oramed Pharmaceuticals during the fourth quarter worth $143,000. Virtu KCG Holdings LLC acquired a new stake in shares of Oramed Pharmaceuticals during the second quarter worth $125,000. Susquehanna International Group LLP acquired a new stake in shares of Oramed Pharmaceuticals during the third quarter worth $185,000. Finally, Renaissance Technologies LLC lifted its stake in shares of Oramed Pharmaceuticals by 12.7% during the fourth quarter. Renaissance Technologies LLC now owns 93,500 shares of the biotechnology company’s stock worth $842,000 after buying an additional 10,500 shares during the period. Institutional investors and hedge funds own 2.08% of the company’s stock.
WARNING: This story was originally published by Daily Political and is owned by of Daily Political. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at https://www.dailypolitical.com/2018/02/23/oramed-pharmaceuticals-ormp-downgraded-to-sell-at-valuengine.html.
Oramed Pharmaceuticals Company Profile
Oramed Pharmaceuticals Inc (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.